Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q1 2017 Earnings Presentation
32 slides from Precigen's earnings presentation, May 10, 2017
Slide 1: First Quarter 2017 Financial Results and Business Update
May 10th, 2017 First Quarter 2017 Financial Results and Business Update Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: Marketable Products & Health
Marketable Products & Health Andrew Last, Ph.D. – Chief Operating Officer
Slide 4: The Next-Generation of Industrial Factories
The Next-Generation of Industrial Factories Human Platform Plant Platform Animal Platform Bacterial Platform Fungal Platform Insect Platform Multi-Cellular Organisms Microbes Intrexon’s platform encompasses the next-generation of biofactories to tackle numerous challenges & deliver on the promise of
Slide 5: Marketable Products
Marketable Products Marketable Products Arctic® Apple First USDA approved non-browning apple without use of chemical or antioxidant treatments AquAdvantage® Salmon First engineered food animal approved by US FDA/Health Canada Friendly™ Aedes Scalable enviro-friendly mosquito solution to suppress the
Slide 6: Advantages of the Arctic Apple
Advantages of the Arctic® Apple Arctic® apples drive benefits across the entire supply chain Convenience for consumer major driver of value in rapidly growing healthy snack market Potential to impact estimated 40% of apples wasted each year Marketable Products
Slide 7: Arctic Non-browning Platform
Arctic® Non-browning Platform Marketable Products Arctic® Apple First USDA approved non-browning apple without use of chemical or antioxidant treatments Commercial launch of fresh sliced Arctic® apples in U.S. in Fall of 2017 US sliced apple market estimated at ~$500 million in sales Non-chemical, p
Slide 8: Friendly Aedes
Friendly™ Aedes Marketable Products Friendly™ Aedes Scalable enviro-friendly mosquito solution to suppress the disease-carrying Aedes aegypti Ongoing geographic expansion in 2017: India – Initiated outdoor caged trials in India to demonstrate the efficacy of Friendly™ mosquitoes in collaboration wit
Slide 9: Durable Suppression with Oxitec's Solution
Durable Suppression with Oxitec’s Solution >80% suppression of Aedes aegypti maintained in second year with release of nearly 60% less Oxitec mosquitoes as compared to year one Level of control illustrative of strength and durability of Oxitec’s solution and indicative of superiority over convention
Slide 10: AquAdvantage Salmon
AquAdvantage® Salmon Marketable Products AquAdvantage® Salmon First engineered food animal approved by US FDA/Health Canada Advantages of AquAdvantage® platform Lower production cost driven by faster growth rate and ~25% less feed requirement No vaccines or antibiotics Land-based production enables
Slide 11: $2 Billion Atlantic Salmon Market in U.S.
$2 Billion Atlantic Salmon Market in U.S.* AquAdvantage® Approach in Aquaculture $157 Billion World Aquaculture Production 2013* AquAdvantage® approach provides a healthy, more sustainable protein source bringing productivity and environmental benefits to the aquaculture industry including reducing
Slide 12: Health Sector & Precigen
INTREXON’ Health Sector & Precigen
Slide 13: Precigen: Focused Gene/Cell Therapy Company
Precigen Precigen Precigen: Focused Gene/Cell Therapy Company Autoimmune & Inflammatory Disease Cardiac Disease Cartilage Repair Human Infertility Infectious Disease Metabolic & GI Disorders Neurodegenerative Disease Neuropathic Pain Oncology Ophthalmology Rare Diseases Respiratory Infection Oral Mu
Slide 14: Health – Clinical Development Outlook for 2017
Indication Gene/Cell Therapy Patient # Phase XON Cost XON Economics Recessive Dystrophic EB FCX-007 1,000-2,500 Phase 1/2 0 14% Net Sales Recurrent Glioblastoma Ad-RTS-IL12 >10,000* Phase 3 0 20% Op Profits Adv. Lymphoid Malignancies Non-viral SB CD19+ CAR T >80,000* Phase 1 0 20% Op Profits Relapse
Slide 15: Next-Gen CAR+ T Platform under RTS Control
Next-Gen CAR+ T Platform under RTS® Control Intrexon, ZIOPHARM Oncology, and biopharmaceutical business of Merck KGaA advancing unique approach to develop therapeutic candidates for two CAR+ T targets expressed on a wide range of tumor types, including hematologic malignancies and solid tumors Disti
Slide 16: Targeting Neoantigens in Solid Tumors
Targeting Neoantigens in Solid Tumors Nat Med. 2016 Jan;22(1):26-36; Mol Ther. 2016 Jun;24(6):1078-89 ZIOPHARM and Intrexon Announce CRADA with National Cancer Institute (NCI) Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens January 2016 June 2016 January 2017 Targeting Neo
Slide 17: Progressing Point-of-Care with CD19 CAR+ T cells
Progressing Point-of-Care with CD19 CAR+ T cells * Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7788-E7797 & ASH 2016, Publication Number 2807 Conditional expression under RTS® gene switch mbIL15 expression can be turned ON, OFF and back ON by addition/removal of veledimex, as shown preclinically
Slide 18: Clinical Trials Update
Clinical Trials Update Intra-tumoral IL-12 RheoSwitch® program (Ad-RTS-hIL-12 + veledimex): In collaboration with investigators and regulators, ZIOPHARM assessing protocol design options for pivotal trial of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma (GBM) and details of pivotal Phase 3 tri
Slide 19: Cardiac Disease: A Significant Unmet Medical Need
Source: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm 25 Million Patients Worldwide 5 Million Patients in U.S. Cardiac Disease: A Significant Unmet Medical Need Angiogenesis Cell Homing Energetics Scar Remodeling Precigen
Slide 20: Xogenex's Unique Three-Gene Approach
Xogenex’s Unique Three-Gene Approach Echocardiographic measurements demonstrated reversal of established ADM cardiomyopathy after a single pXoX treatment in rat model ** P<0.001 PHH3/cTNT/DAPI PHH3/cTNT/DAPI pXoX pStuffer (control) Nuclear localization of phosphohistone H3 (PHH3) mitotic marker conf
Slide 21: Methanotroph Bioconversion Platform (MBP)
Methanotroph Bioconversion Platform (MBP) Robert Walsh – Senior Vice President, Head of Energy Sector
Slide 22: Intrexon Methane Bioconversion Platform
Intrexon Methane Bioconversion Platform Intrexon has developed disruptive MBP technology that enables the profitable use of low cost natural gas to replace oil as the feedstock for several high value industrial products. Need for cleaner burning fuels in automotive and other industries Gas-to-liquid
Slide 23: Natural Gas: Exceptional Source of Carbon
Natural Gas: Exceptional Source of Carbon Source:Bloomberg, Ministry of Economy, Trade and Industry of Japan Industrial Products Division Natural gas (NG) is one of the cheapest sources of carbon available today U.S. EIA estimates over 300 Trillion cubic feet of proven domestic NG reserves Use of NG
Slide 24: Optimal Biological Factory for NG Bioconversion
Optimal Biological Factory for NG Bioconversion Industrial Products Division Intrexon’s Methanotroph Genetic Tools 2014 Present DNA Transformation n/a ✔ DNA Integration & Marker Recycling n/a ✔ Multiple Plasmid Vectors n/a ✔ Multiple Promoters & Regulatory Elements n/a ✔ Advanced Genome Editing n/a
Slide 25: Significant Gas-to-Liquids Opportunity through MBP
Significant Gas-to-Liquids Opportunity through MBP Intrexon’s Engineered Methanotrophs Chemicals achieved: 2,3 Butanediol* Isobutyraldehyde* 1,4 Butanediol* Isoprene Natural Gas Feedstock Fuels achieved: Isobutanol* Farnesene MBP platform has achieved six different molecules to date. The four molecu
Slide 26: Butadiene: $22B Addressable Market with MBP
Butadiene: $22B Addressable Market with MBP Intrexon’s on-purpose butadiene process: 2,3 butanediol Methane bioconversion Catalytic conversion Natural gas Butadiene SOURCE:ICIS, IHS reports Butadiene Market: Global demand for butadiene estimated to be 10.8M metric tons per year in 2015, and projecte
Slide 27: MMA: $7B Addressable Market with MBP
MMA: $7B Addressable Market with MBP esterification Methyl methacrylate Market: Methyl methacrylate (MMA) is a $7B market with a price of $1600-$2200/MT. The principal application is polymethyl methacrylate acrylic plastics (PMMA). PMMA is a resin with high transparency and weather resistance, which
Slide 28: Financial Overview
Financial Overview Joel Liffmann – Senior Vice President, Finance
Slide 29: First Quarter Financial Performance
First Quarter Financial Performance * Non-GAAP financial measure. Select Financial Highlights 1Q 2017 1Q 2016 Revenues $53.7 M $43.4 M Collaboration and Licensing Revenues $33.1 M $24.1 M Product & Services and Other Revenues $20.6 M $19.3 M Adjusted EBITDA $(7.1) M* $(11.7)* Impact of change in def
Slide 30: Portfolio Expansion & Maturation
Portfolio Expansion & Maturation March 2017 1 Over 30 January 2011 Collaborations March 2017 $17.5MM $392Million January 2011 TAF and Received Milestones March 2017 $0 $215 Million January 2011 Cost Recovery Portfolio of Backend Economics Future Milestones & Royalties Financials
Slide 31: Summary
Summary Over 30 collaborations in place capitalizing on our leadership position in the engineering of biology Strong cash position with $205 million in cash, cash equivalents, and short-term investments, and equity securities and preferred stock valued at $156 million Developing high value bio-solut
Slide 32: 1Q 2017 Financial Results and Business Update Q&A Session
1Q 2017 Financial Results and Business Update Q&A Session May 10th, 2017